Drugs / EXG202
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06888492 | Mar 2025 → Apr 2026 overdue | wet macular degeneration | Guangzhou Jiayin Biotech Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07178249 | Oct 2025 → Feb 2028 expected | wet macular degeneration | Guangzhou Jiayin Biotech Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-14 | Exegenesis Bio | Results Exegenesis Bio to Present Data on Next Generation BBB-penetrating AAV Capsids & Intravitreal nAMD Gene Therapy at the American Society of Gene and Cell Therapy Meeting exegenesisbio.com ↗
EXG202: A Next Generation AAV-based Gene Therapy for Neovascular AMD Delivered by Intravitreal Injection with Superior Retinal Transduction in NHPs and Remarkable Inhibitory Effect on Retinal Detachment in a Severe Neovascular Mouse Model |
All press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXG 202 | “EXG 202 is a recombinant adeno-associated virus (rAAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein.” NCT07178249 ↗ |
| Action | Inhibit | “a coding sequence for a soluble anti-VEGF protein” NCT07178249 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “EXG202 is a gene therapy product” NCT06888492 ↗ |
| Route | Intravitreal | “single intravitreal injection” NCT06888492 ↗ |